You are here
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
National Statistics Report Factors In Race, Ethnicity for the First Time
California Woman Claimed Asbestos in Talc-Based Powder Caused Her Mesothelioma
Non-Invasive Therapy for Patients Who are Nonresponsive to Antidepressants
Vials Being Rationed, Only One Manufacturer
Several Health Insurers Now Consider DBS Therapy for Epilepsy a Covered Indication
Policy Could Be Life-Changing for People With Spinal Cord Injury
Health Outcomes Have No Improvement
Treatments Aimed at Rare Diseases Are a Double-edged Sword
Sunshine Law Will be Expanded to Include Nurse Practitioners, Physician Assistants, Nurse-Midwives, and Others
European study concludes clinicians can safely switch patients from originators to biosimilars
Manufacturers Would Still Make a Good Profit If Costs Are Cut, Study Says
Conversely, Kids Who Need Drugs Go Untreated
Says Company’s OxyContin Had “Significant Role” in Opioid Epidemic
Fruquintinib Shows Fewer Side Effects Than Previous VEGFR Inhibitors
Pressure to Rein in Production Persists
Drug Companies Fight Back, Claiming First Amendment Violation
Drugmaker Aiming for 25–30 New Drugs by 2022
HHS proposal designed to prevent ‘Shkrelis,’ not high drug prices overall
Insurers are proceeding cautiously, but the large insurers are speeding up their approvals.
There is a small difference between them and biosimilars that physicians, patients, and insurers should be aware of.
It will nearly quadruple within the next five years, according to a new report, though concerns about how they’re manufactured remain.
Some of that can be chalked up to the differences in cost of living from place to place, but not all.
The move comes even though some of the pharma company’s rivals have promised to raise prices only once a year.
Health plans expected to continue pushing for value-based payment arrangements.
Puts down $700 million to buy nearly 50% of Samsung.
FDA Commissioner Says Agency Needs to Fill Data Gaps as It Looks to Increase Access to Targeted Therapies
Gottlieb spoke at the NCCN Policy Summit on the role of data analytics in drug trials
Some experts still opposed to “right to try” treatments
Agency plans to respond after receipt of letter of concern
But some in industry disagree with the idea